Relapse prevention long-acting treatment for schizophrenia
UZEDY®
Monthly and every-two months subcutaneous risperidone for treatment of schizophrenia, UZEDY is the first treatment based on BEPO® technology approved by the U.S. FDA. UZEDY has been distributed since May 2023 in the United States by Teva (BEPO® technology is licensed to Teva under the name SteadyTeq™).
Strong differentiation thanks to BEPO®
A treatment with options
One injection every 1 or 2 months and no additional starter doses or extra pills once you start UZEDY
Small needle size
One of the smallest LAI needles used to treat schizophrenia
Injected just below the skin
Most other schizophrenia LAIs are injected into muscle
Prefilled syringe
Ready- and easy-to-use, no reconstitution needed
